Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?

Alain Mina, Jose Sandoval Sus, Elsa Sleiman, Javier Pinilla-Ibarz, Farrukh T. Awan, Mohamed A. Kharfan-Dabaja

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Four decades ago, two staging systems were developed to help stratify CLL into different prognostic categories. These systems, the Rai and the Binet staging, depended entirely on abnormal exam findings and evidence of anemia and thrombocytopenia. Better understanding of biologic, genetic, and molecular characteristics of CLL have contributed to better appreciating its clinical heterogeneity. New prognostic models, the GCLLSG prognostic index and the CLL-IPI, emerged. They incorporate biologic and genetic information related to CLL and are capable of predicting survival outcomes and cases anticipated to need therapy earlier in the disease course. Accordingly, these newer models are helping develop better informed surveillance strategies and ultimately tailor treatment intensity according to presence (or lack thereof) of certain prognostic markers. This represents a step towards personalizing care of CLL patients. We anticipate that as more prognostic factors continue to be identified, the GCLLSG prognostic index and CLL-IPI models will undergo further revisions.

Original languageEnglish (US)
Pages (from-to)159-166
Number of pages8
JournalBlood Reviews
Volume32
Issue number2
DOIs
StatePublished - Mar 2018
Externally publishedYes

Fingerprint

Thrombocytopenia
Anemia
Molecular Biology
Patient Care
Therapeutics

Keywords

  • Chronic lymphocytic leukemia
  • Prognostic staging systems
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Mina, A., Sandoval Sus, J., Sleiman, E., Pinilla-Ibarz, J., Awan, F. T., & Kharfan-Dabaja, M. A. (2018). Using prognostic models in CLL to personalize approach to clinical care: Are we there yet? Blood Reviews, 32(2), 159-166. https://doi.org/10.1016/j.blre.2017.10.003

Using prognostic models in CLL to personalize approach to clinical care : Are we there yet? / Mina, Alain; Sandoval Sus, Jose; Sleiman, Elsa; Pinilla-Ibarz, Javier; Awan, Farrukh T.; Kharfan-Dabaja, Mohamed A.

In: Blood Reviews, Vol. 32, No. 2, 03.2018, p. 159-166.

Research output: Contribution to journalReview article

Mina, A, Sandoval Sus, J, Sleiman, E, Pinilla-Ibarz, J, Awan, FT & Kharfan-Dabaja, MA 2018, 'Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?', Blood Reviews, vol. 32, no. 2, pp. 159-166. https://doi.org/10.1016/j.blre.2017.10.003
Mina, Alain ; Sandoval Sus, Jose ; Sleiman, Elsa ; Pinilla-Ibarz, Javier ; Awan, Farrukh T. ; Kharfan-Dabaja, Mohamed A. / Using prognostic models in CLL to personalize approach to clinical care : Are we there yet?. In: Blood Reviews. 2018 ; Vol. 32, No. 2. pp. 159-166.
@article{e2ba274853d743c7b8f70df6b26d331f,
title = "Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?",
abstract = "Four decades ago, two staging systems were developed to help stratify CLL into different prognostic categories. These systems, the Rai and the Binet staging, depended entirely on abnormal exam findings and evidence of anemia and thrombocytopenia. Better understanding of biologic, genetic, and molecular characteristics of CLL have contributed to better appreciating its clinical heterogeneity. New prognostic models, the GCLLSG prognostic index and the CLL-IPI, emerged. They incorporate biologic and genetic information related to CLL and are capable of predicting survival outcomes and cases anticipated to need therapy earlier in the disease course. Accordingly, these newer models are helping develop better informed surveillance strategies and ultimately tailor treatment intensity according to presence (or lack thereof) of certain prognostic markers. This represents a step towards personalizing care of CLL patients. We anticipate that as more prognostic factors continue to be identified, the GCLLSG prognostic index and CLL-IPI models will undergo further revisions.",
keywords = "Chronic lymphocytic leukemia, Prognostic staging systems, Survival",
author = "Alain Mina and {Sandoval Sus}, Jose and Elsa Sleiman and Javier Pinilla-Ibarz and Awan, {Farrukh T.} and Kharfan-Dabaja, {Mohamed A.}",
year = "2018",
month = "3",
doi = "10.1016/j.blre.2017.10.003",
language = "English (US)",
volume = "32",
pages = "159--166",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Using prognostic models in CLL to personalize approach to clinical care

T2 - Are we there yet?

AU - Mina, Alain

AU - Sandoval Sus, Jose

AU - Sleiman, Elsa

AU - Pinilla-Ibarz, Javier

AU - Awan, Farrukh T.

AU - Kharfan-Dabaja, Mohamed A.

PY - 2018/3

Y1 - 2018/3

N2 - Four decades ago, two staging systems were developed to help stratify CLL into different prognostic categories. These systems, the Rai and the Binet staging, depended entirely on abnormal exam findings and evidence of anemia and thrombocytopenia. Better understanding of biologic, genetic, and molecular characteristics of CLL have contributed to better appreciating its clinical heterogeneity. New prognostic models, the GCLLSG prognostic index and the CLL-IPI, emerged. They incorporate biologic and genetic information related to CLL and are capable of predicting survival outcomes and cases anticipated to need therapy earlier in the disease course. Accordingly, these newer models are helping develop better informed surveillance strategies and ultimately tailor treatment intensity according to presence (or lack thereof) of certain prognostic markers. This represents a step towards personalizing care of CLL patients. We anticipate that as more prognostic factors continue to be identified, the GCLLSG prognostic index and CLL-IPI models will undergo further revisions.

AB - Four decades ago, two staging systems were developed to help stratify CLL into different prognostic categories. These systems, the Rai and the Binet staging, depended entirely on abnormal exam findings and evidence of anemia and thrombocytopenia. Better understanding of biologic, genetic, and molecular characteristics of CLL have contributed to better appreciating its clinical heterogeneity. New prognostic models, the GCLLSG prognostic index and the CLL-IPI, emerged. They incorporate biologic and genetic information related to CLL and are capable of predicting survival outcomes and cases anticipated to need therapy earlier in the disease course. Accordingly, these newer models are helping develop better informed surveillance strategies and ultimately tailor treatment intensity according to presence (or lack thereof) of certain prognostic markers. This represents a step towards personalizing care of CLL patients. We anticipate that as more prognostic factors continue to be identified, the GCLLSG prognostic index and CLL-IPI models will undergo further revisions.

KW - Chronic lymphocytic leukemia

KW - Prognostic staging systems

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85032986874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032986874&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2017.10.003

DO - 10.1016/j.blre.2017.10.003

M3 - Review article

C2 - 29122300

AN - SCOPUS:85032986874

VL - 32

SP - 159

EP - 166

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 2

ER -